Zhuang Jianlong, Wang Junyu, Huang Nan, Zheng Yu, Xu Liangpu
Prenatal Diagnosis Center, Quanzhou Women's and Children's Hospital, Quanzhou, 362000, Fujian Province, China.
The teaching and research office of clinical laboratory medicine, Quanzhou Medical College, Quanzhou, 362000, China.
BMC Med Genomics. 2024 Oct 1;17(1):241. doi: 10.1186/s12920-024-02014-2.
Third-generation sequencing (TGS) based on long-read technology has been gradually used in identifying thalassemia and hemoglobin (Hb) variants. The aim of the present study was to explore genotype varieties of thalassemia and Hb variants in Quanzhou region of Southeast China by TGS.
Included in this study were 6,174 subjects with thalassemia traits from Quanzhou region of Southeast China. All of them underwent common thalassemia gene testing using the DNA reverse dot-blot hybridization technology. Subjects who were suspected as rare thalassemia carriers were further subjected to TGS to identify rare or novel α- and β-globin gene variants, and the results were verified by Sanger sequencing and/or gap PCR.
Of the 6,174 included subjects, 2,390 (38.71%) were identified as α- and β-globin gene mutation carriers, including 40 carrying rare or novel α- and β-thalassemia mutations. The αα and Hb Lepore-Boston-Washington were first reported in Fujian province Southeast China. Moreover, the β, β, β-Filipino(~ 45 kb deletion), and Hb Lepore-Quanzhou were first identified in the Chinese population. In addition, 35 cases of Hb variants were detected, the rare Hb variants of Hb Jilin and Hb Beijing were first reported in Fujian province of China. Among them, one case with compound ααα and Hb G-Honolulu variants was identified in this study.
Our findings may provide valuable data for enriching the spectrum of thalassemia and highlight the clinical application value of TGS-based α- and β-globin genetic testing.
基于长读长技术的第三代测序(TGS)已逐渐应用于地中海贫血和血红蛋白(Hb)变异体的鉴定。本研究旨在通过TGS探索中国东南部泉州地区地中海贫血和Hb变异体的基因型多样性。
本研究纳入了来自中国东南部泉州地区的6174例地中海贫血特征患者。所有患者均采用DNA反向点杂交技术进行常见地中海贫血基因检测。疑似罕见地中海贫血携带者的患者进一步接受TGS检测,以鉴定罕见或新型的α和β珠蛋白基因变异体,并通过桑格测序和/或缺口PCR验证结果。
在纳入的6174例患者中,2390例(38.71%)被鉴定为α和β珠蛋白基因突变携带者,其中40例携带罕见或新型的α和β地中海贫血突变。αα和Hb Lepore-Boston-Washington首次在中国东南部福建省被报道。此外,β、β、β-Filipino(约45 kb缺失)和Hb Lepore-Quanzhou首次在中国人群中被鉴定。此外,检测到35例Hb变异体,其中罕见的Hb Jilin和Hb Beijing变异体首次在中国福建省被报道。其中,本研究鉴定出1例复合ααα和Hb G-Honolulu变异体。
我们的研究结果可能为丰富地中海贫血谱提供有价值的数据,并突出基于TGS的α和β珠蛋白基因检测的临床应用价值。